csirt@kutim:~/threat-intel/cve/CVE-2026-12127

Katalog CVE

CVSS 5.3 · Medium EPSS 0,60%

Kerentanan Improper Neutralization of CRLF Sequences ('CRLF Injection'). Skor CVSS 3.1 5.3 (Medium) menurut wordfence.com.

Deskripsi (NVD)

The WPForms – Easy Form Builder for WordPress – Contact Forms, Payment Forms, Surveys, & More plugin for WordPress is vulnerable to Improper Neutralization of CRLF Sequences ('CRLF Injection') in all versions up to, and including, 1.10.2 This is due to `get_reply_to_address()` processing the Reply-To display name through smart-tag expansion with context `'notification'` instead of `'notification-reply-to'`, which bypasses email-address validation while `wpforms_sanitize_textarea_field()` intentionally preserves CR/LF characters that are never stripped before the display name is concatenated into the raw `Reply-To:` mail header string. This makes it possible for unauthenticated attackers to inject arbitrary additional email headers — such as `Bcc:` — into outgoing notification emails, silently blind-copying all notification email copies to an attacker-controlled address. Exploitation requires that a form notification is configured to use a Paragraph Text (textarea) field as the Reply-To display name via a Smart Tag.

Rincian

Terbit di NVD
1 Juli 2026
Terakhir diubah
1 Juli 2026
Status NVD
Deferred
CVSS 3.1
5.3 (Medium), sumber wordfence.com
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:L/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-93: Improper Neutralization of CRLF Sequences ('CRLF Injection')
EPSS (30 hari)
0,60% peluang dieksploitasi; lebih tinggi dari 47,0% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.